Day Historical Balance Sheet
| DAWN Stock | USD 13.72 0.38 2.85% |
Trend analysis of Day One Biopharmaceuticals balance sheet accounts such as Total Current Liabilities of 31 M or Total Stockholder Equity of 363.9 M provides information on Day One's total assets, liabilities, and equity, which is the actual value of Day One Biopharmaceu to its prevalent stockholders. By breaking down trends over time using Day One balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Day One Biopharmaceu latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Day One Biopharmaceu is a good buy for the upcoming year.
Day |
About Day Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Day One Biopharmaceu at a specified time, usually calculated after every quarter, six months, or one year. Day One Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Day One and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Day currently owns. An asset can also be divided into two categories, current and non-current.
Day One Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Day One assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Day One Biopharmaceu books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Day One balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Day One Biopharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents Day One obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Day One Biopharmaceu are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Day One Biopharmaceu balance sheet. This account contains Day One investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Day One Biopharmaceuticals fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most accounts from Day One's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Day One Biopharmaceu current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. At this time, Day One's Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 25th of November 2024, Short and Long Term Debt Total is likely to grow to about 506.8 K, while Total Assets are likely to drop about 239.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 6.5M | 15.5M | 26.1M | 27.4M | Total Assets | 289.8M | 349.1M | 376.0M | 239.3M |
Day One balance sheet Correlations
Click cells to compare fundamentals
Day One Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Day One
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.Moving against Day Stock
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 1.144 | Return On Assets (0.25) | Return On Equity (0.18) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.